Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen
Adult
Graft Rejection
Male
Adolescent
Histocompatibility Testing
Incidence
Siblings
Graft vs Host Disease
Bacteremia
Bacterial Infections
Middle Aged
Antiviral Agents
ABO Blood-Group System
3. Good health
03 medical and health sciences
0302 clinical medicine
Blood Group Incompatibility
Cytomegalovirus Infections
Humans
Female
Ganciclovir
Aged
Stem Cell Transplantation
DOI:
10.1038/sj.leu.2403105
Publication Date:
2003-08-20T20:26:54Z
AUTHORS (17)
ABSTRACT
In the setting of reduced-intensity conditioning (RIC) regimens for allogeneic stem cell transplantation (allo-SCT), the epidemiology of transplant-related infections is still poorly defined. In 101 high-risk patients who received an HLA-identical sibling allo-SCT after RIC, including fludarabine, busulfan and antithymocyte globulin (ATG), we report during the first 6 months a cumulative incidence of positive CMV antigenemia of 42% (95% CI 32-52%), developing at a median of 37 (range 7-116) days without evidence of CMV disease (median follow-up, 434 days). The cumulative incidence of bacteremia was 25% (95% CI 17-33%), occurring at a median of 67 (range 7-172) days, while patients had recovered a full neutrophil count. In all, 65% of the bacteremia (95% CI 49-81%) were gram negative. The cumulative incidence of fungal infections was 8% (95% CI 3-13%), with a median onset of 89 (range 7-170) days. In multivariate analysis, stem cell source (bone marrow; P=0.0002) was significantly associated with the risk of positive CMV antigenemia, while higher doses of prednisone (>2 mg/kg) represented the major risk factor for bacteremia (P=0.0001). Infectious-related mortality was 5% (95% CI 1-9%), with aspergillosis being the principal cause. Collectively, these results suggest that prospective efforts are warranted to develop optimal antimicrobial preventive strategies after RIC allo-SCT.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (58)
CITATIONS (88)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....